Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
  Barrierefreiheit    Kontakt MedUni Wien    Intranet    MedUni Wien - Shop    Universitätsbibliothek    Universitätsklinikum AKH Wien  
 
ccc_logo_en.gif
 
AKH Wien
 
 
Hauptnavigation
  • Livestream 2021
  • Home
  • Über das CCC
    • Allgemeines
    • Leitung der Organisationseinheit
    • CCC-Office Team
    • Kliniken und Partner
    • Qualitätsmanagement
    • Kontakt
  • PatientInnen
    • Covid-19
    • Allgemeines
    • Cancer School
    • Terminvereinbarung
    • Pflegeambulanz
    • PatientInnenvertretung
    • Links
  • Klinischer Bereich
    • Allgemeines
    • CCC Tumorboards
  • Wissenschaft & Forschung
    • Young CCC
    • CCC-ExpertInnenvideos
    • CCC Forschungscluster
    • CCC Units
    • CCC Platforms
    • Translationale Forschung
    • CCC Best Paper Award
    • CCC-TRIO Symposium
    • Kontakt/Links
  • Lehre
    • CCC Cancer School
    • Vienna International Summer School on Clinical and Experimental Oncology - VSSO
    • CCC Excellence Lecture
    • Interdisziplinäre onkologische Ausbildung
    • Klinisch-Praktisches Jahr (KPJ)
    • PhD Programme
    • Postgraduelle Fort- und Weiterbildung
    • Information/Contact
 
 
Subnavigation
    Inhaltsbereich


    Zurück zur Übersicht
    HGG advances. 2020 Aug 25. doi: 10.1016/j.xhgg.2020.100010. pii: S2666-2477(20)30010-5. pmc: PMC8756515
    Hemochromatosis risk genotype is not associated with colorectal cancer or age at its diagnosis.
    Jarvik GP1,  Wang X2,  Fontanillas P3,  Kim E4,  Chanprasert S5,  Gordon AS6,  Bastarache L7,  Kowdley KV8,  Harrison T9,  Rosenthal EA10,  Stanaway IB11,  Bézieau S12,  Weinstein SJ13,  Newcomb PA14,  Casey G15,  Platz EA16,  Visvanathan K17,  Le Marchand L18,  Ulrich CM19,  Hardikar S20,  Li CI21,  van Duijnhoven FJB22,  Gsur A23,  Campbell PT24,  Moreno V25,  Vodička P26,  Brenner H27,  Chang-Claude J28,  Hoffmeister M29,  Slattery ML30,  Gunter MJ31,  Aglago EK32,  Castellví-Bel S33,  Kweon SS34,  Chan AT35,  Li L36,  Zheng W37,  Bishop DT38,  Giles GG39,  Rennert G40,  Offit K41,  Keku TO42,  Woods MO43,  Hampe J44,  Van Guelpen B45,  Gallinger SJ46,  de la Chapelle A47,  Hampel H48,  Berndt SI49,  Tangen CM50,  Lindblom A51,  Wolk A52,  Burnett-Hartman A53,  Wu AH54,  White E55,  Gruber SB56,  Jenkins MA57,  Mountain J58,  Peters U59,  Crosslin DR60
    Author information
    1University of Washington Medical Center, Seattle, WA, USA.
    2Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
    323andMe, Sunnyvale, CA, USA.
    423andMe, Sunnyvale, CA, USA.
    5University of Washington Medical Center, Seattle, WA, USA.
    6Northwestern University, Evanston, IL, USA.
    7Vanderbilt Medical Center, Atlanta, GA, USA.
    8Liver Institute Northwest, Seattle, WA, USA.
    9Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
    10University of Washington Medical Center, Seattle, WA, USA.
    11University of Washington Medical Center, Seattle, WA, USA.
    12Centre Hospitalier Universitaire (CHU) Nantes, France.
    13National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
    14Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
    15University of Virginia, Charlottesville, VA, USA.
    16Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
    17Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
    18University of Hawaii Cancer Center, Honolulu, HI, USA.
    19University of Utah, Salt Lake City, UT, USA.
    20University of Utah, Salt Lake City, UT, USA.
    21Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
    22Division of Human Nutrition and Health, Wageningen University and Research Wageningen, the Netherlands.
    23Medical University Vienna, Vienna, Austria.
    24American Cancer Society, Atlanta, GA, USA.
    25Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP) and Department of Clinical Sciences, Faculty of Medicine, University of Barcelona (UB), L'Hospitalet, 08908, Barcelona, Spain.
    26Institute of Experimental Medicine, Czech Academy of Sciences, Biomedical Center, Medical Faculty Pilsen and 1st Medical Faculty, Charles University, Prague, Czech Republic.
    27German Cancer Research Center (DKFZ), Heidelberg, Germany.
    28German Cancer Research Center (DKFZ), Heidelberg, Germany.
    29German Cancer Research Center (DKFZ), Heidelberg, Germany.
    30University of Utah, Salt Lake City, UT, USA.
    31Nutrition and Metabolism Section, International Agency for Research on Cancer (IARC-WHO), Lyon, France.
    32Nutrition and Metabolism Section, International Agency for Research on Cancer (IARC-WHO), Lyon, France.
    33Gastroenterology Department, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
    34Chonnam National University Medical School, Gwangju, Korea.
    35Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
    36University of Virginia, Charlottesville, VA, USA.
    37Division of Epidemiology, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
    38University of Leeds, Leeds, UK.
    39Cancer Council Victoria, Melbourne, VIC, Australia.
    40Lady Davis Carmel Medical Center, Haifa, Israel.
    41Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    42University of North Carolina, Chapel Hill, NC, USA.
    43Memorial University of Newfoundland, St. John's, NL, Canada.
    44Technische Universität Dresden (TU Dresden), Dresden, Germany.
    45Department of Radiation Sciences, Oncology, Umeå University and Wallenberg Centre for Molecular Medicine, Umeå University, Sweden.
    46University of Toronto, Toronto, ON, Canada.
    47The Ohio State University, Columbus, OH, USA.
    48The Ohio State University, Columbus, OH, USA.
    49National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
    50Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
    51Karolinska University Hospital, Stockholm, Sweden.
    52Karolinska Institutet, Stockholm, Sweden.
    53Kaiser Permanente Colorado, Denver, CO, USA.
    54University of Southern California, Los Angeles, CA, USA.
    55Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
    56City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
    57Centre for Epidemiology and Biostatistics, School of Population and Global Health, The University of Melbourne, VIC, Australia.
    5823andMe, Sunnyvale, CA, USA.
    59Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
    60University of Washington Medical Center, Seattle, WA, USA.
    Abstract

    Homozygotes for the higher penetrance hemochromatosis risk allele, c.845G>A (p.Cys282Tyr, or C282Y), have been reported to be at a 2- to 3-fold increased risk for colorectal cancer (CRC). These results have been reported for small sample size studies with no information about age at diagnosis for CRC. An association with age at diagnosis might alter CRC screening recommendations. We analyzed two large European ancestry datasets to assess the association of genotype with CRC risk and age at CRC diagnosis. The first dataset included 59,733 CRC or advanced adenoma cases and 72,351 controls from a CRC epidemiological study consortium. The second dataset included 13,564 self-reported CRC cases and 2,880,218 controls from the personal genetics company, 23andMe. No association of the common hereditary hemochromatosis (HH) risk genotype and CRC was found in either dataset. The odds ratios (ORs) for the association of CRC and C282Y homozygosity were 1.08 (95% confidence interval [CI], 0.91-1.29; p = 0.4) and 1.01 (95% CI, 0.78-1.31, p = 0.9) in the two cohorts, respectively. Age at CRC diagnosis also did not differ by C282Y/C282Y genotype in either dataset. These results indicate no increased CRC risk in individuals with HH genotypes and suggest that persons with HH risk genotypes can follow population screening recommendations for CRC.


    © 2020 The Authors.

    KEYWORDS: HFE gene, age of onset, colon cancer, ferritin, genetic, iron, population screening

    Publikations ID: 35047832
    Quelle: öffnen
     
    Drucken
     
    ccc_logo_en.gif
    ccc_logo_en.gif
    ccc_logo_en.gif

    Schnellinfo

     
    -- Initiative Krebsforschung / Krebsforschungslauf

    -- Cancer Care
    -- Kliniken und Partner
    -- CCC Cancer School
    -- Young CCC
    -- CCC Tumorboards
    -- CCC Forschungscluster
    -- CCC Units
    -- CCC Platforms
    -- SOPs / Leitlinien
    -- Kontakt
    Zuklappen
     
    Ausklappen
     
     

    Featured

     
     
     
     
     
     
     
     
     
     
     
     
     
    © MedUni Wien |
     Impressum | Nutzungsbedingungen | Kontakt